James William Kupiec Sells 4,000 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) Stock

Cassava Sciences, Inc. (NASDAQ:SAVA) insider James William Kupiec sold 4,000 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $3.87, for a total value of $15,480.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Cassava Sciences Trading Down 2.6 %

NASDAQ:SAVA opened at $3.35 on Wednesday. The stock has a market capitalization of $161.17 million, a P/E ratio of -2.43 and a beta of -0.86. Cassava Sciences, Inc. has a 1 year low of $3.25 and a 1 year high of $42.20. The firm has a 50 day moving average of $23.95 and a 200-day moving average of $22.52.

Cassava Sciences (NASDAQ:SAVA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.79. During the same quarter in the prior year, the business posted ($0.61) EPS. As a group, analysts forecast that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on SAVA. HC Wainwright cut shares of Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price objective on the stock. in a research report on Tuesday, November 26th. Rodman & Renshaw reaffirmed a “buy” rating and set a $107.00 target price on shares of Cassava Sciences in a research report on Thursday, August 8th.

Institutional Trading of Cassava Sciences

Institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new position in shares of Cassava Sciences in the 3rd quarter valued at approximately $10,610,000. KBC Group NV acquired a new position in shares of Cassava Sciences in the third quarter valued at approximately $57,000. CANADA LIFE ASSURANCE Co increased its position in shares of Cassava Sciences by 146.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 9,408 shares of the company’s stock worth $191,000 after acquiring an additional 5,594 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Cassava Sciences by 1.4% during the first quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company’s stock worth $47,813,000 after acquiring an additional 31,854 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in shares of Cassava Sciences by 18.1% during the second quarter. Bank of New York Mellon Corp now owns 140,847 shares of the company’s stock worth $1,739,000 after acquiring an additional 21,558 shares during the period. Institutional investors and hedge funds own 38.05% of the company’s stock.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.